Related Experiment Video
Updated: May 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer
LaMont J Barlow1, Mitchell C Benson
1Department of Urology, Herbert Irving Comprehensive Cancer Center, Herbert Irving Pavilion, Columbia University Medical Center, 11th Floor 161 Fort Washington Ave., New York, NY 10032, USA. ljb2119@columbia.edu
Abstract:
The definitive treatment for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical bacillus Calmette-Guérin (BCG) is cystectomy. However, many patients who experience recurrence after BCG are either poor operative candidates or refuse surgery due to the long-term impact on their quality of life. In the last decade, there has been an increased interest in alternative intravesical therapies, and several novel chemotherapeutics have emerged as promising agents for high-risk NMIBC patients unable or unwilling to undergo cystectomy. Additionally, extended treatment regimens with combined induction and maintenance therapy have been investigated, and may increase the durability of response to these new agents, as has been shown for conventional intravesical therapy.
Related Concept Videos
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Treatment Resistant Cancers